Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$0.00$0.00— vs Q1 2016 Net Income-$2.80M-$2.80MN/M vs Q1 2016 EPS Diluted-$0.01-$0.01— vs Q1 2016 Operating Income-$2,813,072N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2017 · filed May 8, 2017 · 38 d after period end